Abcam, ab213480, Anti-PD-L1 antibody [EPR20529]

Size: 20µL / 100µL / 1mL
Anti-PD-L1 antibody [EPR20529] (ab213480) is a rabbit monoclonal antibody detecting PD-L1 in Western Blot, IP, ICC/IF . Suitable for Mouse . - KO validated for confirmed specificity - Biophysical QC for unrivalled batch-batch consistency - Over 70 publications
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR20529,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse,
Applications:IP, WB, ICC/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:This antibody is not suitable in IHC-FR for mouse samples

Product details:
Anti-PD-L1 antibody [EPR20529] (ab213480) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in ICC/IF, IP and WB.
Abcam's high quality manufacturing and validation processes ensure Anti-PD-L1 antibody [EPR20529] (ab213480) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.
The specificity of Anti-PD-L1 antibody [EPR20529] (ab213480) has been confirmed by Western Blot testing in PD-L1 knockout MEF (mouse embryonic fibroblast) cells.
Anti-PD-L1 antibody [EPR20529] (ab213480) has 5 independent reviews from customers.
Anti-PD-L1 antibody [EPR20529] (ab213480) specifically detects PD-L1 (UniProt ID: Q9EP73; Molecular weight: 31kDa) and is sold in 100 µL and 1 mL selling sizes.
Conjugation-ready, carrier free format available for antibody clone EPR20529 -
ab223141
Programmed death-ligand 1 (PD-L1) is a critical protein in immuno-oncology, playing a significant role in tumor immune evasion. It is expressed on the surface of tumor cells and binds to the PD-1 receptor on T cells, inhibiting their activity and allowing tumors to escape immune detection.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.
Biological function summary
PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.
Pathways
PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.
PD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.